Lergotrile
Lergotrile is a potent and orally active dopamine agonist and a prolactin secretion inhibitor. Lergotrile inhibits prolactin release from pituitaries by activating an adenohypophyseal dopamine receptor. Lergotrile has the potential for the research of Parkinson's disease.
For research use only. We do not sell to patients.
- CAS No.: 36945-03-6
- Formula: C17H18ClN3
- Molecular Weight:299.80
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Dopamine Receptor Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sympathetic neuron | ED50 |
0.27 μM/kg
Compound: 2
|
Compound tested in vivo for sympathetic neuronal activity in cat cardioaccelerator nerve after iv administration
Compound tested in vivo for sympathetic neuronal activity in cat cardioaccelerator nerve after iv administration
|
[PMID: 6699883] |
| Sympathetic neuron | ED50 |
0.27 μmol/Kg
Compound: 2
|
Compound tested in vivo for sympathetic neuronal activity in cat cardioaccelerator nerve after iv administration
Compound tested in vivo for sympathetic neuronal activity in cat cardioaccelerator nerve after iv administration
|
[PMID: 6699883] |
Chemical Information
-
CAS No. 36945-03-6
-
Molecular Weight 299.80
-
Formula C17H18ClN3
-
SMILES
ClC1=C2C3=C(N1)C=CC=C3[C@]4([H])[C@@](N(C[C@@H](C4)CC#N)C)([H])C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
Purity & Documentation
References
[1]. Clemens JA, et al. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action. Acta Endocrinol (Copenh). 1975 Jun;79(2):230-7. [Content Brief]
[2]. Lemberger L, et al. The inhibitory effect of an ergoline derivative (lergotrile, compound 83636) on prolactin secretion in man. J Clin Endocrinol Metab. 1974 Sep;39(3):579-84. [Content Brief]
[3]. Lieberman A, et al. Treatment of Parkinson's disease with lergotrile mesylate. JAMA. 1977 Nov 28;238(22):2380-2. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lergotrile Related Classifications
HY-107002 Related Classifications
Powered by Bioz